Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models

por Entchev, Eugeni, Jantzen, Ingrid, Masson, Philippe, Bocart, Stephanie, Bournique, Bruno, Luccarini, Jean-Michel, Bouchot, Andre, Lacombe, Olivier, Junien, Jean-Louis, Broqua, Pierre, Tallandier, Mireille
Publicado 2020

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

por Derrett-Smith, Emma, Clark, Kristina E. N., Shiwen, Xu, Abraham, David J., Hoyles, Rachel K., Lacombe, Olivier, Broqua, Pierre, Junien, Jean Louis, Konstantinova, Irena, Ong, Voon H., Denton, Christopher P.
Publicado 2021